New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Generate Biomedicines, Inc. (GENB) vs MannKind Corporation (MNKD)
- Generate Biomedicines, Inc. GENB 10.02 −3.47%
- MannKind Corporation MNKD 3.91 −0.76%
Generate Biomedicines, Inc. and MannKind Corporation are both Biotechnology companies. Generate Biomedicines, Inc. and MannKind Corporation are of similar size ($1.4B and $1.3B). MannKind Corporation has the higher net margin (−18.1% vs −1,326.8%) and the lower return on invested capital (−2.58% vs 0.00%). Across the 15 metrics below, MannKind Corporation leads on 9 and Generate Biomedicines, Inc. on 6.
Valuation
Profitability
| Metric | GENB | MNKD | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 75.76% | 70.18% |
| Operating margin | (1,382.04%) | (2.88%) | 0.00% |
| Net margin | (1,326.75%) | (18.10%) | 0.00% |
| Free cash flow margin | (1,199.36%) | (18.97%) | 0.00% |
| Return on equity | 1,047.66% | 182.90% | (51.58%) |
| Return on assets | (54.06%) | (12.29%) | (45.91%) |
| Return on invested capital | 0.00% | (2.58%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack